Seller review · costs and terms
altRx review
altRx publishes monthly product figures but leaves selected term and testing details unresolved. Its policy can make payment final before fulfillment, with a three-day cancellation window for future renewals.
By Jenna Pratt, consumer-access reporter · Updated October 2026
Itemized bill
altRx
Totals are our arithmetic from the seller’s published figures. Extra fees unconfirmed: the seller states no amount for patient laboratory services. Confirm these charges and the medication price before paying.
The bill, in one line
Confirm the term, total payment and medical-disqualification deductions before paying. Cancel-anytime language stops future billing under the policy; it does not promise a refund of the purchased term.
The altRx policies describe a bundled subscription containing clinical, platform and appropriate pharmacy services, with independent OpenLoop professionals responsible for prescribing decisions. The selected package and purchase term determine what the buyer receives and which recurring charges can be stopped. They also settle what has already been purchased.
The product pages display compounded semaglutide at $89 per month and tirzepatide at $149, alongside a dashboard illustration showing a three-month subscription. That illustration does not conclusively establish the term qualifying for either headline, so confirm the actual collection and commitment before assuming an independent monthly purchase. Professional and platform components are bundled and product FAQs include delivery, while laboratory allowances can vary and still need confirmation for the chosen term.
Fees outside the headline
Bundled platform accessincluded
The subscription terms include applicable platform-access fees in one total, not a separate zero-cost claim.
Read October 2026
Bundled clinical reviewincluded
The total subscription price includes applicable clinical services; the selected term still matters.
Read October 2026
Listed product deliveryincluded
The product FAQ explicitly includes shipping.
Read October 2026
Patient laboratory servicesnot published
The policy permits laboratory services where applicable without one universal patient allowance.
Read October 2026
See altRx’s current price
Check the seller’s own page before you pay.
The fine print
- Prepay
- The refund policy covers single-month and multi-month plans, treating longer bundles as indivisible purchases without refunds for unused time or undelivered medicine. Having several available plan types does not identify which one qualifies for the headline, so confirm the applicable term before authorizing payment.
- Cancellation
- Contact patient support at least seventy-two hours before the next billing date; account cancellation may also be available under the selected arrangement. A request inside that window can leave another nonrefundable cycle payable, while stopping future renewal does not refund the current purchased term. Medical disqualification can permit a limited refund after deductions for used clinical review, prescription, laboratory or pharmacy services; it is not an unconditional full-refund promise. Ask how the company values those used components before payment, because that calculation can determine the amount returned when treatment cannot continue.
- Shipping
- Product FAQs include delivery, but the policy generally makes replacement the remedy for damaged or incorrect items and requires prompt reporting with evidence. FDA’s June 8, 2026 warning to Trinity HealthCare Supply, LLC dba altRx addresses misleading marketing and label identity for compounded semaglutide and tirzepatide. That record does not establish a defect in every shipment or an automatic refund right, and current disclaimers do not establish FDA closeout.
FDA warning letters
- Letter 728236: FDA primary letter
Worth it, and what to watch
Worth it
- Bundled charge structure explained
- Renewal notice window stated
- Medical-disqualification exception addressed
Watch for
- Selected term not established by the headline
- Refunds can close at payment
- Testing scope and deduction values unclear
- Buy here if
- A buyer who will obtain the complete selected-term invoice and understand medical-disqualification deductions before authorizing the subscription.
- Look elsewhere if
- A buyer expecting cancel-anytime wording to refund unused prepaid service or assuming all outside testing is covered.
Price it elsewhere
Other sellers that publish a matching price. Sellers we have reviewed come first, then sellers we have only priced; each group runs lowest price first.
FAQ
3 questionsDoes timely cancellation refund the paid term?
The policy says cancellation stops future renewal without refunding the current term, so unused time should not be treated as an automatic refund.
Is medical disqualification always a complete refund?
The medical-disqualification exception can deduct used services under the policy, making the purchased components and their assigned values important to clarify before payment.
Does the FDA warning establish every order is defective?
The cited FDA record addresses specific marketing and labeling representations, without establishing that every order is defective or that a particular patient received affected medicine.
Price it at altRx
Every figure above was read from altRx’s own pages. The current one is a click away.
Questions the research answers
Other sellers we have priced
| Nex Gen Health Rx | $57.32/mo, Glutathione injection |
|---|---|
| Contour Health | $60/mo, NAD+ injection |
| Collective | $76/mo, Semaglutide injection |
| Avono Health | $79/mo, Semaglutide injection |
| Lean Meds | $79/mo, Semaglutide injection |
| RxPepsDirect | $80 per vial, Sermorelin injection |
| Enhanced | $89/mo, Semaglutide injection |
| Citizen Meds | $91/mo, NAD+ injection |
Where every figure comes from
- Current semaglutide route, figures, evidence and pharmacy FAQ
- Current tirzepatide route and figure
- OpenLoop and bundled financial roles
- Clinical consent and outcome-data disclosure
- Payment finality, notice and exception terms
- Direct June8,2026 FDA warning and precise findings